San Diego drugmaker Acadia Pharmaceuticals Inc. is looking to raise $200 million in a secondary offering.

The company, which recently got FDA approval of its antipsychotic drug Nuplazid, just raised $300 million back in January. Combined with cash already in the bank, Acadia should have close to $600 million after the new capital raise.

What’s the cash for? Well, the commercial launch of its first drug has not come cheap. Acadia chose to launch Nuplazid solo – without a commercial partner with existing sales and marketing infrastructure. At the company’s current burn rate of $70 million per quarter, Acadia has enough cash to last until the third quarter of 2017.

The drug’s potential, however, could get the company in the green sometime in the future. Needham & Co. analyst Alan Carr previously estimated that Nuplazid would earn $500 million in annual sales to start, but with potential to reach over a billion in annual sales if the drug is prescribed for other indications such as Alzheimer’s and schizophrenia.

Acadia is already in later-stage human trials in those indications, and extra cash will help the company achieve development milestones.

The timing of Acadia’s new equity raise seems appropriate, considering the improved mood of the market.

Acadia’s stock (Nasdaq: ACAD) is down over 5 percent on the news, currently trading for $33.34 per share.